Showing results (1-10 of 275) with videos related to
Sort By:
Pageof 28
Ultrasound in Medicine & Biology|September 29, 2014
Diagnostic impact of color Doppler ultrasound-guided core biopsy on fine-needle aspiration of anterior mediastinal massesHung-Jen Chen, Wei-Chih Liao, Shinn-Jye Liang, et al.Diagnostics (Basel, Switzerland)|January 8, 2023
The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung CancerWen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, et al.Cancers|February 11, 2023
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational StudyWen-Chien Cheng, Yi-Cheng Shen, Chieh-Lung Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 15, 2010
Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort studyYang-Hao Yu, Chien-Chang Liao, Wu-Huei Hsu, et al.BMC Cancer|May 22, 2022
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from TaiwanChieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, et al.Thoracic Cancer|April 8, 2022
The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from TaiwanWen-Chien Cheng, Yi-Cheng Shen, Chun-Ru Chien, et al.BMC Cancer|September 11, 2023
A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinomaChieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, et al.BMC Cancer|February 19, 2024
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational studyWen-Chien Cheng, Chi-Chien Lin, Wei-Chih Liao, et al.BMC Pulmonary Medicine|October 16, 2024
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIsHsu-Yuan Chen, Chia-Hung Chen, Wei-Chih Liao, et al.Cancer Medicine|March 29, 2024
Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategyWei-Chun Chen, Wen-Chien Cheng, Chieh-Lung Chen, et al.Pageof 28